In the last 12 months, insiders at Unicycive Therapeutics, Inc. ($UNCY) filed 54 transactions with the SEC: 0 open-market purchases totaling $0 and 0 sales totaling $0. Net insider sentiment: neutral.
Unicycive Therapeutics, Inc. operates in the Pharmaceutical preparations industry (Life sciences sector).
Most Active Insiders
- Aggarwal Gaurav (Director) — 15 transactions totaling $22,734,210
- Jermasek Douglas (EVP of Corporate Strategy) — 10 transactions totaling $100,000
- Gupta Shalabh K. (CEO) — 10 transactions totaling $100,000
- Gupta Pramod (EVP, Pharmaceuticals and BD) — 10 transactions totaling $40,000
- Laumas Sandeep (Director) — 2 transactions totaling $0
View all SEC Filings for Unicycive Therapeutics, Inc. (UNCY).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug. 25, 2025 | Aggarwal Gaurav | Director | C | Common Stock | 652900 | $0.00 | 1,789,915.0000 | 12,302,059 | 57.42% | 5.31% |
| Aug. 25, 2025 | Aggarwal Gaurav | Director | D | Series A-2 Prime Preferred Stock | 3199 | $1000.00 | 0.0000 | 12,302,059 | 100.00% | 0.03% |
| July 28, 2025 | Townsend John | Chief Financial Officer | A | Stock Options | 10000 | $0.00 | 101,557.0000 | 12,302,059 | 10.92% | 0.08% |
| July 28, 2025 | Gupta Pramod | EVP, Pharmaceuticals and BD | A | Stock Options | 90000 | $0.00 | 301,986.0000 | 12,302,059 | 42.46% | 0.73% |
| July 28, 2025 | Jermasek Douglas | EVP of Corporate Strategy | A | Stock Options | 10000 | $0.00 | 215,500.0000 | 12,302,059 | 4.87% | 0.08% |
| July 28, 2025 | Laumas Sandeep | Director | A | Stock Options | 21200 | $0.00 | 41,286.0000 | 12,302,059 | 105.55% | 0.17% |
| July 28, 2025 | Gupta Shalabh K. | CEO | A | Stock Options | 325000 | $0.00 | 968,951.0000 | 12,302,059 | 50.47% | 2.64% |
| July 28, 2025 | Kenkare-Mitra Sara | Director | A | Stock Options | 21200 | $0.00 | 39,200.0000 | 12,302,059 | 117.78% | 0.17% |
| July 28, 2025 | Aggarwal Gaurav | Director | A | Stock Options | 21200 | $0.00 | 39,200.0000 | 12,302,059 | 117.78% | 0.17% |
| Feb. 18, 2025 | Aggarwal Gaurav | Director | C | Common Stock | 1400000 | $0.00 | 11,370,152.0000 | 66,985,129 | 14.04% | 2.09% |
| Feb. 18, 2025 | Aggarwal Gaurav | Director | D | Series A-2 Prime Preferred Stock | 686 | $1000.00 | 3,119.2100 | 66,985,129 | 18.03% | 0.00% |
| Oct. 9, 2024 | Aggarwal Gaurav | Director | C | Common Stock | 5500000 | $0.00 | 9,970,152.0000 | 8,894,321 | 123.04% | 61.84% |
| Oct. 9, 2024 | Aggarwal Gaurav | Director | D | Series A-2 Prime Preferred Stock | 2695 | $1000.00 | 3,885.2100 | 8,894,321 | 40.96% | 0.03% |
| Aug. 12, 2024 | Gupta Pramod | EVP, Pharmaceuticals and BD | A | Stock Options | 81750 | $0.00 | 2,119,862.0000 | 9,405,285 | 4.01% | 0.87% |
| Aug. 12, 2024 | Townsend John | Chief Financial Officer | A | Stock Options | 40256 | $0.00 | 915,565.0000 | 9,405,285 | 4.60% | 0.43% |
| Aug. 12, 2024 | Jermasek Douglas | EVP of Corporate Strategy | A | Stock Options | 81750 | $0.00 | 2,055,000.0000 | 9,405,285 | 4.14% | 0.87% |
| Aug. 12, 2024 | Gupta Shalabh K. | CEO | A | Stock Options | 232868 | $0.00 | 6,439,505.0000 | 9,405,285 | 3.75% | 2.48% |
| April 15, 2024 | Gupta Pramod | EVP, Pharmaceuticals and BD | A | Stock Options | 463250 | $0.00 | 2,038,112.0000 | 34,912,692 | 29.42% | 1.33% |
| April 15, 2024 | Gupta Shalabh K. | CEO | A | Stock Options | 1319583 | $0.00 | 6,206,637.0000 | 34,912,692 | 27.00% | 3.78% |
| April 15, 2024 | Jermasek Douglas | EVP of Corporate Strategy | A | Stock Options | 463250 | $0.00 | 1,973,250.0000 | 34,912,692 | 30.68% | 1.33% |
| April 15, 2024 | Townsend John | Chief Financial Officer | A | Stock Options | 228119 | $0.00 | 875,309.0000 | 34,912,692 | 35.25% | 0.65% |
| Sept. 5, 2023 | Laumas Sandeep | Director | A | Stock Options | 189236 | $0.00 | 200,864.0000 | 15,234,570 | 1627.42% | 1.24% |
| Sept. 5, 2023 | Kenkare-Mitra Sara | Director | A | Stock Options | 180000 | $0.00 | 180,000.0000 | 15,234,570 | 9999.99% | 1.18% |
| Sept. 5, 2023 | Ryan John L | Director | A | Stock Options | 112147 | $0.00 | 123,775.0000 | 15,234,570 | 964.46% | 0.74% |
| Sept. 5, 2023 | Aggarwal Gaurav | Director | A | Stock Options | 180000 | $0.00 | 180,000.0000 | 15,234,570 | 9999.99% | 1.18% |
| Aug. 28, 2023 | Townsend John | Chief Financial Officer | A | Stock Options | 570329 | $0.00 | 647,190.0000 | 15,234,570 | 742.03% | 3.74% |
| Aug. 28, 2023 | Gupta Pramod | EVP, Pharmaceuticals and BD | A | Stock Options | 1355000 | $0.00 | 1,574,862.0000 | 15,234,570 | 616.30% | 8.89% |
| Aug. 28, 2023 | Gupta Shalabh K. | CEO | A | Stock Options | 4684775 | $0.00 | 4,988,798.0000 | 15,234,570 | 1540.93% | 30.75% |
| Aug. 28, 2023 | Jermasek Douglas | EVP of Corporate Strategy | A | Stock Options | 1355000 | $0.00 | 1,510,000.0000 | 15,234,570 | 874.19% | 8.89% |
| July 11, 2023 | Aggarwal Gaurav | Director | C | Common Stock | 3470152 | $0.00 | 3,470,152.0000 | 15,234,570 | 9999.99% | 22.78% |
| July 11, 2023 | Aggarwal Gaurav | Director | C | Series A-1 Preferred Stock | 8077 | $1000.00 | 0.0000 | 15,234,570 | 100.00% | 0.05% |
| July 11, 2023 | Aggarwal Gaurav | Director | C | Series A-2 Preferred Stock | 13429000 | $0.00 | 13,429,000.0000 | 15,234,570 | 9999.99% | 88.15% |
| July 11, 2023 | Aggarwal Gaurav | Director | C | Tranche A Warrants (right to buy) | 12802388 | $0.00 | 12,802,388.0000 | 15,234,570 | 9999.99% | 84.04% |
| July 11, 2023 | Aggarwal Gaurav | Director | C | Tranche B Warrants (right to buy) | 11638534 | $0.00 | 11,638,534.0000 | 15,234,570 | 9999.99% | 76.40% |
| July 11, 2023 | Aggarwal Gaurav | Director | C | Tranche C Warrants (right to buy) | 18621655 | $0.00 | 18,621,655.0000 | 15,234,570 | 9999.99% | 100.00% |
| July 11, 2023 | Jermasek Douglas | EVP of Corporate Strategy | M | Common Stock | 104612 | $0.00 | 175,012.0000 | 15,234,570 | 148.60% | 0.69% |
| July 11, 2023 | Jermasek Douglas | EVP of Corporate Strategy | M | Series A-1 Convertible Preferred Stock | 50 | $1000.00 | 0.0000 | 15,234,570 | 100.00% | 0.00% |
| July 11, 2023 | Jermasek Douglas | EVP of Corporate Strategy | M | Warrant (right to buy | 79252 | $0.00 | 79,252.0000 | 15,234,570 | 9999.99% | 0.52% |
| July 11, 2023 | Jermasek Douglas | EVP of Corporate Strategy | M | Warrant (right to buy) | 72047 | $0.00 | 72,047.0000 | 15,234,570 | 9999.99% | 0.47% |
| July 11, 2023 | Jermasek Douglas | EVP of Corporate Strategy | M | Warrant (right to buy) | 115275 | $0.00 | 115,275.0000 | 15,234,570 | 9999.99% | 0.76% |
| July 11, 2023 | Gupta Pramod | EVP, Pharmaceuticals and BD | M | Common Stock | 41845 | $0.00 | 41,845.0000 | 15,234,570 | 9999.99% | 0.27% |
| July 11, 2023 | Gupta Pramod | EVP, Pharmaceuticals and BD | M | Series A-1 Convertible Preferred Stock | 20 | $1000.00 | 0.0000 | 15,234,570 | 100.00% | 0.00% |
| July 11, 2023 | Gupta Pramod | EVP, Pharmaceuticals and BD | M | Warrant (right to buy | 31700 | $0.00 | 31,700.0000 | 15,234,570 | 9999.99% | 0.21% |
| July 11, 2023 | Gupta Pramod | EVP, Pharmaceuticals and BD | M | Warrant (right to buy) | 28818 | $0.00 | 28,818.0000 | 15,234,570 | 9999.99% | 0.19% |
| July 11, 2023 | Gupta Pramod | EVP, Pharmaceuticals and BD | M | Warrant (right to buy) | 46110 | $0.00 | 46,110.0000 | 15,234,570 | 9999.99% | 0.30% |
| July 11, 2023 | Gupta Shalabh K. | CEO | M | Common Stock | 104612 | $0.00 | 2,527,449.0000 | 15,234,570 | 4.32% | 0.69% |
| July 11, 2023 | Gupta Shalabh K. | CEO | M | Series A-1 Convertible Preferred Stock | 50 | $1000.00 | 0.0000 | 15,234,570 | 100.00% | 0.00% |
| July 11, 2023 | Gupta Shalabh K. | CEO | M | Warrant (right to buy | 79252 | $0.00 | 79,252.0000 | 15,234,570 | 9999.99% | 0.52% |
| July 11, 2023 | Gupta Shalabh K. | CEO | M | Warrant (right to buy) | 72047 | $0.00 | 72,047.0000 | 15,234,570 | 9999.99% | 0.47% |
| July 11, 2023 | Gupta Shalabh K. | CEO | M | Warrant (right to buy) | 115275 | $0.00 | 115,275.0000 | 15,234,570 | 9999.99% | 0.76% |
| March 8, 2023 | Aggarwal Gaurav | Director | A | Series A-1 Convertible Preferred Stock | 8077 | $1000.00 | 8,077.0000 | 15,057,049 | 9999.99% | 0.05% |
| March 8, 2023 | Gupta Shalabh K. | CEO | A | Series A Convertible Preferred Stock | 50 | $1000.00 | 50.0000 | 15,057,049 | 9999.99% | 0.00% |
| March 8, 2023 | Gupta Pramod | EVP, Pharmaceuticals and BD | A | Series A Convertible Preferred Stock | 20 | $1000.00 | 20.0000 | 15,057,049 | 9999.99% | 0.00% |
| March 8, 2023 | Jermasek Douglas | EVP of Corporate Strategy | A | Series A Convertible Preferred Stock | 50 | $1000.00 | 50.0000 | 15,057,049 | 9999.99% | 0.00% |